Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04936529 · ClinicalTrials.gov registry record · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
A Phase 2 study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
- 1
- Study location
NCT04936529: Recruiting Phase 2 study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04936529 is a Phase 2 study of Neuroblastoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 286 participants, above the 236-participant average among 94 other Neuroblastoma trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04936529, a Phase 2 study of Neuroblastoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.
Primary Outcome
Effect of GM-CSF on anti-GD2 antibody titers among patients who are in first or second (or later) CR, i.e., have no evidence of NB by standard studies.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT β-glucan
- DRUG GM-CSF
- BIOLOGICAL OPT-821
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
What NCT04936529 shows while recruiting
NCT04936529 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, above the 236-participant average among 94 other Neuroblastoma trials with a reported enrollment target (21% higher).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which β-glucan is the first listed.
NCT04936529 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04936529 about?
NCT04936529 is a clinical study titled "A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma". The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The com...
What is the current status of trial NCT04936529?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2021-08-02. Estimated completion is 2026-06-15.
What conditions does trial NCT04936529 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT04936529?
The interventions under investigation include: β-glucan (DIETARY_SUPPLEMENT), GM-CSF (DRUG), OPT-821 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04936529?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04936529 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04936529's enrollment target sits among peer trials
286 15th of 94 higher than 80 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
- NCT05987592 · 286 participants · NA
BE WELL With Migraine: Brain Education and WELLness With Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI